Benefit from anthracyclines in relation to biological profiles in early breast cancer

[1]  J. Bartlett,et al.  Chromosome instability and benefit from adjuvant anthracyclines in breast cancer , 2012, British Journal of Cancer.

[2]  Mark T. W. Ebbert,et al.  Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial , 2012, Clinical Cancer Research.

[3]  R. Peto,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. , 2012, Lancet.

[4]  M. Beckmann,et al.  Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. , 2012, Breast.

[5]  C. Sotiriou,et al.  HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. , 2011, The Lancet. Oncology.

[6]  J. Olson,et al.  Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  E. Scarpi,et al.  Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer , 2011, Breast Cancer Research and Treatment.

[8]  J. Bartlett,et al.  Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge , 2010, Oncogene.

[9]  C. Caldas,et al.  Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). , 2010, The Lancet. Oncology.

[10]  G. Hortobagyi,et al.  Role of anthracyclines in the treatment of early breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Robin L. Jones,et al.  The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer , 2009, Breast Cancer Research and Treatment.

[12]  F. Penault-Llorca,et al.  Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Thomas J. Hardcastle,et al.  Chromosomal instability determines taxane response , 2009, Proceedings of the National Academy of Sciences.

[14]  C. Perou,et al.  Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Prescott,et al.  Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Gilcrease,et al.  Ki-67 as Prognostic Marker in Early Breast Cancer: A Meta-analysis of Published Studies Involving 12 155 Patients , 2008 .

[17]  R. Venkatraman.  HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials , 2008 .

[18]  Irene L Andrulis,et al.  HER2 and responsiveness of breast cancer to adjuvant chemotherapy. , 2006, The New England journal of medicine.

[19]  Jens Overgaard,et al.  retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Amadori,et al.  Quality Control for Biomarker Determination in Oncology: The Experience of the Italian Network for Quality Assessment of Tumor Biomarkers (INQAT) , 2002, The International journal of biological markers.

[21]  M. Untch,et al.  HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer , 2001, Breast Cancer Research and Treatment.

[22]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[23]  B Fisher,et al.  erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. , 1998, Journal of the National Cancer Institute.

[24]  O. Nanni,et al.  Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: A prospective study , 1997, Breast Cancer Research and Treatment.

[25]  F. O'Malley,et al.  Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial , 2011, Breast Cancer Research and Treatment.

[26]  R. Peto.  EARLY BREAST-CANCER TRIALISTS COLLABORATION , 1987 .